Meeder Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Meeder Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186K	Buy	+5,009	New	+$162K	0.01%	306
2022 Q3	–	Sell	-33	Closed	-$1K	–	2169
2022 Q2	$1K	Hold	33	–	–	﹤0.01%	1993
2022 Q1	$1K	Hold	33	–	–	﹤0.01%	2154
2021 Q4	$1K	Buy	+33	New	+$1.44K	﹤0.01%	1013
2018 Q3	–	Sell	-126	Closed	-$954	–	1561
2018 Q2	$954	Buy	126 +88	+232%	+$1.18K	﹤0.01%	1504
2018 Q1	$1K	Buy	38 +14	+58%	+$542	﹤0.01%	1443
2017 Q4	$1K	Buy	+24	New	+$1.03K	﹤0.01%	1556
2017 Q3	–	Sell	-63	Closed	-$2K	–	1641
2017 Q2	$2K	Sell	63 -56	-47%	-$2.48K	﹤0.01%	1388
2017 Q1	$6K	Sell	119 -230	-66%	-$12K	﹤0.01%	996
2016 Q4	$19K	Buy	+349	New	+$19.9K	﹤0.01%	663

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's CLDX Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 5,009 shares worth $186K. The stake represents 0.01% of the portfolio and ranks #306 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in CLDX as recently as Q2 2022.

Meeder Asset Management first reported a position in CLDX in Q4 2016 and has held it in 10 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Meeder Asset Management held 5,009 shares of Celldex Therapeutics worth $186K as of Q2 2026.
Celldex Therapeutics was a new Meeder Asset Management position in Q2 2026.
Celldex Therapeutics made up 0.01% of Meeder Asset Management's portfolio in Q2 2026, its #306 holding.
Meeder Asset Management first reported a position in Celldex Therapeutics in Q4 2016 and has held it in 10 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.